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Incidence and Management of Polypharmacy 




There is a growing concern related to poly pharmacy in various generations with a special 
interest in elderly. The geriatric population is at high risk of having various chronic illness and in 
turn uses multiple medications for their chronic illness. When talking about polypharmacy, what 
would one expect to see? What are the incidences related to polypharmacy and how can that be 
managed? Polypharmacy is described as having prescriptions of multiple drugs. Other definitions 
state polypharmacy as the use of multiple medications. No article seems to define the number of 
drugs that can be considered as multiple. Other articles have number ranges from five to twenty 
or more medications. Poly pharmacy is hence addressed as a general use of various medications 
both over the counter and prescription. The goal of this paper is to make our society aware of the 
need to review and reconcile patients’ medications in order to reduce the negative incidence and 
management of polypharmacy.  
  
Incidence and Management of Polypharmacy 




"I woke up this morning feeling shakily and my heart pounding. It felt as though I was 
going to die and I was scared to call ambulance. I thought I should just come in and see you." 
This was a statement told to a primary care provider from a geriatric patient during a routine 
follow up visit. Upon assessment and review of the patient’s medications, the provider noted that 
the patient had been taking the wrong time and amount of his Flomax. He was taking at least 
seven medications and most of them were to be taken two to three times a day. He had 
understood that he should take the capsule three times a day. On his medication list he had 
omeprazole and Flomax that were both capsules. According to his previous visit, his 
understanding was to take the capsules three times a day and since he picked both bottle after 
that visit he was not able to differentiate the two and took the Flomax versus the omeprazole 
three times a day.  
Another example was a 78-year-old female leaving independently in an assisted living 
managing her medications independently with at least six comorbidities including but not limited 
to diabetes, chronic kidney failure, and hypertension. She had been hospitalized four times 
within the past month with hypoglycemia episodes. Prior to all her admissions she had been 
managing her diabetes with metformin and maintained blood glucose levels with 100 – 250 
mg/dl. Her hemoglobin A1C was 7.5. Upon further assessment the provider noted that she had 
been taking her short-acting insulin three times a day and her blood glucose was very low during 
the night. She was taking her last snack at 7pm and going to bed per her previous routine. She 
had maintained using the short-acting per teaching that she had received at the hospital three 
times a day, not considering the carbohydrates she was taking. Review of her hospital records 
indicate that she was eating at least six carbohydrates with every meal while at the hospital. Her 
Incidence and Management of Polypharmacy 
   5 
 
  
metformin had been discontinued and she was to start on both short- and long-acting insulin. Her 
blood glucose was managed well due to a structured setting and her meals being monitored. 
While at the assisted living she was making her own choices on the meal she was taking. She 
was still taking metformin per her old records and added the insulin to her list. That played a 
huge impact on her blood glucose since she had been scheduled to take six units of Novolog 
three times a day and taking metformin twice day. This caused the frequent hypoglycemic 
episodes because most days she was taking at least three or less carbohydrates, then snacking in 
between per her old routine.  
Polypharmacy may have indications as above due to poor understanding of one’s 
medication management. The need for providers to take time and review patients’ medications 
may be relevant in reducing incidence and managing polypharmacy. Ferner & Aronson (2006) 
state that in an ideal situation prescribing information should have the potential side effects of 
every drug, whereby one should be able to know probability of harm in relation to the dose, time 
and factors that alter one’s susceptibility. Communicating therefore can enable patients’ 
awareness on what kinds of medications they are taking and a better understanding of potential 
side effects.  
Research has shown that the incidence of polypharmacy occurs more with older adults 
especially in the geriatric populations who have a higher rate of chronic comorbidities. This 
increases their chance of having multiple prescriptions for various disease processes. Steinman, 
Lund, Miao, Boscardin, & Kaboli, (2011) completed a study that showed the adverse drug 
effects to geriatric patients, and how drug interactions increased functional impairments such as 
falls, and cognitive status. This study also showed the probability of adverse drug interactions 
hinder the older adults or geriatrics from functioning at an optimal level. For instance using 
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antihypertensive can increase risks of orthostatic blood pressure when patients have impaired 
vascular tone, they are unable to compensate the physiological changes caused by the 
medications. This would then increase the rate of falls in this population and may lead to another 
comorbidity like fracture or limited mobility due to pain.  
Managing polypharmacy may be difficult when patients have or use various providers 
that need to be in direct communication with all changes on medication prescription. This can be 
an issue with patients that utilize specialty services on multiple concerns. An example is a patient 
that has an oncologist, hematologist, cardiology, and a primary care provider. If a clear line of 
treatment is not indicated, the patient would receive medications or procedures that can be 
repeated in another clinic. Steinman, Lund, Miao, Boscardin, & Kaboli, (2011) explains that 
ongoing review of drug interactions is necessary; stating that adverse drug reactions can be noted 
at early stages of initiating a new medication. Therefore caution is needed when starting new 
medications, with a recommendation of initiating one drug at a time or discontinuing one drug at 
time. It would also benefit patients to have a follow up visit with their primary care providers 
less than seven days after discharge to review their recent admission and current plan being 
maintained after discharge.  
Case Report 
Chief Complaint: 87 year old female at the clinic for a follow up visit after a recent admission 
with urinary tract infection and fatigue for 3 days. She is also feeling dizzy.  
HPI: 
Ms. E.M is at the clinic today for a follow up visit after a recent discharge. She reports feeling 
much better and denies having dysuria, frequency, urgency or lower back pain. She reports that 
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she has been taking her antibiotic and has at least 3 doses left to finish her dosage. She denies 
having a fever or chills and denies pain. She is c/o of dizziness and fatigue that is ongoing, she 
states that the dizziness is more in the morning when she awaken or move from a sitting to 
standing. She denies having vertigo and states that the dizziness resolves when she takes time or 
rests in between moving positions. Other than her current medications she is not taking any 










Donepezil 5 mg po daily 
Fluticasone proprionate and salmeterol 250/50 1 puff bid 
Losartan 50 mg po daily 
Metoprolol 50 mg po daily 
Gabapentin 300 mg tid 
Paroxetine 20 mg po daily 
Quetiapine 200 mg po bid 
Insulin glargine 30 units’ SQ qhs 
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Nitrofurantoin ER 100 mg po bid X 7 days (3 days left) 
Multivitamin po daily 




She does not smoke, no alcohol use or illicit drug use. 
Personal and family history: 
She resides in an assisted living facility; has a daughter; medications are managed at the assisted 
living  
REVIEW OF SYSTEM: 
Constitution: she denies having fever or chills 
HEENT: denies having headache, c/o of dizziness; denies having trouble hearing or with her eye 
sight and uses glasses. Denies having nasal drainage or sinus concerns. Denies having dysphagia  
Cardiovascular: denies having edema 
Respiratory: denies having SOB or dyspnea;  
GI: denies having abdominal pain 
GU: denies dysuria or frequency; denies nausea or emesis; denies constipation 
Musculoskeletal: states that she is independent at the assisted living 
Physical Examination: 
V/S: BP 88/40; P 50; R 24; T 98.6 
FSBS this morning 107 
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Constitution: she is alert and oriented x 3; does not appear to be in any acute distress; groomed 
appropriately for the season  
HEENT: head – atraumatic; eyes – wears glasses; ear – symmetrical with no visible deformity; 
nose- no drainage and nares are patent, denies sinus pressure; throat – able to swallow, thyroid 
midline.  
Cardiovascular: Normal S1 and S2; no edema 
Respiratory: Lung sounds are clear with no distress, no wheezing or rales 
GI: abdomen is soft and non-tender; positive bowel sounds  
GU: CVS negative; denies dysuria or frequency; denies nausea or emesis; denies constipation 
Musculoskeletal: observed to be ambulatory  
Assessment & Plan 
Differential Diagnosis: Drug interaction; Hypotension; Anemia; Bradycardia;  
Drug Interaction – currently on various medication with probability of drug interaction. No 
clinical indication for some of the medications. 
Plan – will review and discontinue one medication at a time with follow up as needed and 
review with pharmacist on contraindications. Initial medication to be discontinued will be 
Quetiapine/Seroquel on the next visit. 
Hypotension – Blood pressure 88/40 with complaints of dizziness; on metoprolol 50 mg daily  
with side effects causing dizziness and fatigue. 
Plan – Will reduce metoprolol to 25 mg po daily and continue to monitor blood pressure daily, 
with nurse visit and report blood pressures lower than 80/40, c/o of dizziness, lightheadedness, 
fatigue, diarrhea, confusion. 
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Anemia – Currently on iron and multivitamin supplements, has complaints of fatigue that has 
been ongoing experience. CBC - WNL; Iron studies – WNL; ferritin - WNL 
Plan – will continue with current treatment plan of iron supplements and reassess on fatigue 
within 1 week.  
 
A Review of Literature  
A literature review was completed in order to assess the incidence, causes, and 
management of polypharmacy. The research was done using databases such as PubMed, 
CINAHL, Medline, and Cochrane. The keywords included “Polypharmacy in geriatric”, 
“Incidence in polypharmacy”, and Management of polypharmacy”.  Numerous articles that were 
peer reviewed and had the word “Polypharmacy”, were further evaluated for this paper. They 
were then narrowed down using the articles summaries or conclusion to help determine their 
association with the current topic. Articles that addressed using the keywords “incidences and 
management of polypharmacy” were selected and also further reviewed. A total of sixteen 
articles were considered relevant and related well with the topic. Those articles reviewed 
prevalence and negative effects of polypharmacy, and interventions that could help manage 
polypharmacy. Some articles indicated common adverse and drug interactions related to 
polypharmacy. A further review of the articles was done to selectively use articles with most 
literature on incidence, causes and management of polypharmacy, which narrowed the articles 
down to ten.   
Incidence and Causes of Polypharmacy 
Sganga, et. al. (2015) reports that polypharmacy is related to hospitalization of older 
adults and complex disease processes. Reports in the article explain that the use of polypharmacy 
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has an increased the rate of adverse reactions. These adverse reactions may lead to 
hospitalization. The article states that patients taking at least seven drugs or more have a higher 
chance of medication error. Explaining that older adults that have many drugs, at times lack a 
good medication management like a pill box and could forget the drugs that they took increasing 
a chance of error or doubling the doses. 
Marcum, Thorpe, Gellad, & Donohue, (2014) explain that using numerous pharmacies 
versus one/similar pharmacy may increase the likelihood of polypharmacy. The authors also 
indicate that multi pharmacy was associated with higher medication non adherence, poor 
communication with providers, patients and pharmacists. The article explains that when 
considering work loads of pharmacists, chances of overrides, lack of a complete medication 
history and the multi pharmacy use can also cause incidents such as use of warfarin and anti-
inflammatories leading to gastrointestinal bleeding. Communication therefore plays an important 
role in reducing the incidences of polypharmacy. Field, Gurwitz, Avorn, et. al (2001), the study 
was completed on long term care patients that had multiple drugs. The study showed that a 
number of the patients had an adverse drug effect at some point in the study that was either life 
threatening, serious or fatal. The study concluded that adverse drug effects were preventable, 
recommending reducing the number of drugs that were being taken, reviewing indications of use 
more often and reducing prescription. Reviewing drugs can be done with a multisystem approach 
by using various team members like medical assistants, clinic nurses, providers, pharmacies 
among other providers that have the knowledge and understanding of being able to check which 
medications patients are taking.  
Fried, et. al. (2014), show that polypharmacy was a marker for poor health since most 
people that take multiple medications had a number of co-morbidities. The study expected to 
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show that polypharmacy was related to fall risks, adverse drug reactions events, hospitalization, 
mortality, physical and cognitive impairment. However, the results indicated an independent 
relationship between polypharmacy and outcomes for example medications and mortality in 
older adults found no mortality benefit.  
Management of Polypharmacy 
Spinewine, et. al. (2007) explains that since the geriatric population has a wide 
heterogeneity with health conditions ranging from fit to frail, it is not appropriate to generalize 
their cares or prescribing decisions. They further elaborate that medications being a fundamental 
part of their care, providers should use good measures to prescribe medications that are 
beneficial to these age groups. The article uses three values to judge for appropriateness which 
include, what the patient wants, scientific or technical rationalism which includes the clinical 
pharmacology of the drug and the general good. When understanding “what the patient wants”, 
provider should listen to patients’ and know what they are experiencing. A cent example is a 
patient that came to the clinic with concerns on occasional numbness to their bilateral wrists and 
were worried that they could be having a stroke due to their family history. Upon assessment and 
review of their system, there were no red flags indicating a stroke. On examination the patient 
then stated that they have noticed the numbness when sleeping with their hand under the head. 
Often it has been a habit they have developed due to a recent shift change. On days that they 
have a day off and nap in their bed, the complaint has not been evident. Most differential 
diagnosis were negative and the conclusion was that they must be pinching their nerves when 
sleep laying their head on their hands. A change of that habit and follow up within 2 weeks 
resolved the concern. O medications were needed in this case and so many other cases that one 
may come across in the field. At times patients’ feel better talking with their providers for 
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assurance versus medication initiation. Various studies indicate that using geriatric medicine 
service approaches, having pharmacist involvement in reviewing contraindications, patient care 
and computerized decision support can improve the appropriateness of prescribing in geriatrics.  
Sganga, et. al. (2015) explains that using a pill box can help manage medications and 
organize the times those medications are taken thereby reducing drug interactions or over dose 
related to doubling the doses. Ferner & Aronson, (2006) states that an understanding of 
prescription medications by providers and patients can help manage polypharmacy and may 
reduce drug incidences. An example is knowing the common side effects of medications and 
being able to identify the changes like an increased level of prothrombin time in a patient taking 
Coumadin may be related to a drug interaction with a new drug or change. The article concluded 
that more research and resources are needed to support providers with appropriate information to 
help both providers and patients make informed decisions when prescribing and taking 
medications. Marcum, Thorpe, Gellad, & Donohue, (2014) states that pharmacies can manage 
and may reduce polypharmacy by using the pharmacy software which can randomly checks for 
possible alerts that hence prevent drug interactions from occurring.  
Tan, Eastment, Poudel, & Hubbard, (2015) also reaffirms the importance of providers 
informing their patients and ensuring that they understanding which medications they have been 
prescribed, the risks and benefits of the drug, and their goal of care. When patients are informed, 
they can make informed decision to take the medications and hopefully update their providers 
when they suspect that they are experiencing side effects. Patients can be able to identify which 
medication they recently changed and clue in the providers to take a closer approach on 
addressing the concern versus treating a side effect of a medication that could probably be 
discontinued and resolve the problem.  The center for disease control and prevention (2010) 
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explains in an article that the use of new medications can be used to improve one’s quality of 
life. However, the article also states that inappropriate prescription can be detrimental to one’s 
health thereby as earlier shown in this paper an understanding of medication use should be well 
known before prescribing the medications. Providers and patients need to be aware of which 
medications they are taking, taking initiatives like reading the paper work provided to patients’ 
by the pharmacist or having a consult at the pharmacy for all new medications that they are 
receiving.  
World health organization (2012) concludes with 12 interventions that are relevant 
toward managing polypharmacy “ establishing of a multidisciplinary national body to coordinate 
policies on medicine use; use of clinical guidelines; development and use of national essential 
medicines list; establishment of drug and therapeutic committees in districts and hospitals; 
inclusion of problem-based pharmacotherapy training in undergraduate curricula; continuing in-
service medical education as a licensure requirement; supervision, audit and feedback; use of 
independent information on medicines; public education about medicines; avoidance of perverse 
financial incentives; use of appropriate and enforced regulation; sufficient government 
expenditure to ensure availability of medicines and staff”. The above steps if implemented 
throughout the health systems, incidence and management of polypharmacy can be attained.  
Learning Points 
• Communication is a key to managing polypharmacy, when patients and providers 
are informed of the potential risks versus the benefits, they will more than likely 
use available resources to reduce harm. For instance patients can quickly and 
easily identify changes which need to be reported to their providers. Providers 
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would also have screening in place to prevent harm like having routine blood 
count on patients taking clozapine. With open communication harm can be 
detected early and interventions placed to maintain safety.    
• Collaboration with other team members. When patients are seen with providers, a 
quick review of the patients’ medications would be relevant. Using resources 
available at various clinics and hospitals like the use of pharmacists to evaluate 
the clinical need of the medications they are taking and address possible 
contraindications. Having clinic nurses’ complete follow up calls to at risk 
patients that start new medications to confirm their understanding.  
• Educating patients of expected and unexpected actions on their current 
medications. An example providing essential tools like automated blood pressure 
cuffs and having patients keep records of their reading. Ensuring that patients’ 
that are diabetic bring their glucose meters to their primary care provider 
appointments for a closer look into their blood glucose readings. Reviewing the 
levels with the patients and providing teaching on events that seem unclear or 
reinforcing better control of the levels. 
• Being advocates for patients and addressing concerns that are recognized at the 
clinic or hospital with appropriate interventions. For instance when a provider 
sees a patient that is elderly and is at risk of polypharmacy related to poor 
management of her medications. Providers should initiate an in home assessment 
for medication management if covered by insurance. Providers can also have 
house calls paramedics that visit people at home to help manage their medications 
and reduce incidences that can be caused with poor medication management. 
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• Self-efficacy in patients can also attribute to managing polypharmacy. This can be 
achieved by patients having the motivation to make it when circumstances change 
and not rely on medications to help sort out their problems. Having the ability to 
recognize that not all disease processes are treated with antibiotics or pain 
medications, being able to pursue non pharmacological interventions like physical 
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